Phase 3 study of sirolimus for posterior segment uveitis achieves primary endpoint

Santen Inc. announced that its first of two global phase 3 studies analyzing the efficacy and safety of intravitreal injections of sirolimus in noninfectious posterior segment uveitis patients has met its primary endpoint.The Study Assessing Double‐Masked Uveitis Treatment (SAKURA), achieved a predetermined number of patients with a vitreous haze score of zero at 5 months, according to the release.

Full Story →